Bio-Rad Laboratories, Inc. (BIO) Stock Analysis and Metrics

Bio-Rad Laboratories

NYSE: BIO

$314.70 ▼ -1.68 (-0.53%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap8.53 Bn

P/E50.54

P/S3.29

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)1.20 Bn

Revenue Growth (1y) (Qtr)1.14

Add ratio to table…

About

Bio-Rad Laboratories, Inc. is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables. The company operates globally with direct operations in over 36 countries outside the United States through subsidiaries focused on sales, customer service, and product distribution, supplemented by distributors and agents in certain locations. Bio-Rad serves research, biopharmaceutical, clinical, and industrial markets with products designed for separating, purifying, characterizing, and quantifying biological materials.

Bio-Rad generates revenue through the sale of instruments, systems, reagents, and consumables across its Life Science and Clinical Diagnostics segments. In the Life Science segment, revenue comes from products used in research, biopharmaceutical manufacturing, quality control, food safety testing, and science education. In the Clinical Diagnostics segment, revenue is derived from diagnostic test systems, informatics solutions, test kits, and specialized quality controls for clinical laboratories. A significant portion of Clinical Diagnostics revenue is recurring due to standardized platforms that drive ongoing sales of test kits and consumables.

The company operates through the following segments: Life Science and Clinical Diagnostics.

• The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used to separate, purify, characterize, and quantify biological materials including cells, proteins, and nucleic acids. These products are utilized in research and biopharmaceutical laboratory environments, as well as in biopharmaceutical manufacturing, quality control processes, food safety testing, and science education applications. The segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, and food producers and testing laboratories worldwide.

• The Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics solutions, test kits, and specialized quality controls for clinical laboratories in the global diagnostics market. Its products address targeted segments within the in vitro diagnostics market with a focus on differentiated diagnostic applications. The segment supplies several thousand products supporting more than 300 clinical diagnostic tests and consists of reagents, instruments, and software provided as integrated systems to support standardized laboratory workflows and reproducible test results. Principal customers include hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Bio-Rad holds a strong position in the competitive life science and diagnostics industries. In the Life Science segment, major competitors include Becton Dickinson, Danaher, Merck KGaA, Qiagen N. V., and Thermo Fisher Scientific. In the Clinical Diagnostics segment, key competitors are Abbott Laboratories, Becton Dickinson, bioMérieux, Danaher, DiaSorin, Werfen, QuidelOrtho, Roche, Siemens Healthineers, Thermo Fisher Scientific, and Tosoh. The company competes based on meeting performance specifications, technical support, comprehensive solutions, quality, service, and product portfolio breadth.

Bio-Rad serves a broad and diversified global customer base that includes university and research institutions, hospital and public health laboratories, commercial laboratories, diagnostic manufacturers, and companies in the biotechnology, pharmaceutical, chemical, and food industries. Specific customer types referenced in the filing include universities, medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, testing laboratories, hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Investment Thesis

▲ Bull case

The integration of Stilla Technologies provides a tangible catalyst for accelerating growth in the high-margin ddPCR portfolio, with management explicitly raising the full-year 2025 revenue growth outlook for this segment from low single-digit to mid-single-digit, which directly contributes to the upward revision of the Life Science business guidance from flat to down 3% to flat to 1% for the full year. This is not merely an additive effect; the combination of the QX Continuum and QX700 Series products is strategically positioned to expand the ddPCR market by targeting lower-throughput customers through simplified workflows and flexible pricing, thereby capturing share from traditional qPCR users and unlocking new applications in clinical diagnostics where partners like Incyte Molecular Diagnostics and Genoscopy are advancing FDA-cleared assays for kidney transplant monitoring and colon cancer screening—both of which have achieved significant milestones such as NCCN guideline inclusion, creating a de facto reimbursement pathway that could drive durable, recurring reagent sales independent of volatile academic funding cycles. The market appears to be underestimating the structural shift toward ddPCR as a complementary or even preferred technology to NGS for specific use cases due to its speed, cost efficiency, and precision, a trend that could sustain growth even if academic instrument demand remains soft.
Despite persistent softness in the academic and biotech research markets, Bio-Rad is demonstrating resilience through durable consumable demand, particularly in its Droplet Digital PCR and food safety segments, which are less sensitive to capital expenditure cycles and more tied to recurring operational needs. The company noted that consumable demand from academic customers is proving more durable than prior expectations, a trend supported by high single-digit growth in ddPCR consumables year-over-year and stabilization in food safety sales, which continue to grow at high single-digit rates due to their application in regulated, non-discretionary markets like food safety and environmental testing. This durability is further reinforced by the shift in customer behavior toward maintaining research continuity despite funding uncertainty, as highlighted by management’s observation that academic customers are “focused on keeping their people and keeping the research going,” translating into sustained assay and reagent usage even when instrument purchases are deferred. This dynamic creates a predictable, annuity-like revenue stream that mitigates the cyclicality traditionally associated with life science equipment sales and provides a buffer against macroeconomic headwinds.
The company’s proactive management of tariff exposure has significantly reduced a previously feared headwind, with management revising the estimated tariff impact on operating margin from up to 130 basis points to just 30–40 basis points, a direct result of supply chain diversification, supplier collaboration, and increased manufacturing flexibility—including replicated capabilities and adaptive sourcing strategies—that were implemented without overinvestment amid uncertainty. This operational agility, combined with the easing of trade tensions with China and delayed tariff implementations elsewhere, has allowed Bio-Rad to upgrade its full-year 2025 non-GAAP gross margin guidance to 53.5%–54.5% (from 53%–54.5%) and operating margin to 12%–13% (from 10%–12%), reflecting not just cost control but improved absorption from manufacturing efficiencies and favorable product mix shifts driven by consumable pull-through. The market may be overlooking how these structural supply chain improvements—born from necessity but now embedded in operations—could become a lasting competitive advantage, enabling the company to maintain margin resilience even if geopolitical tensions resurge, and positioning it to outperform peers less prepared for such volatility.

The integration of Stilla Technologies provides a tangible catalyst for accelerating growth in the high-margin ddPCR portfolio, with management explicitly raising the full-year 2025 revenue growth outlook for this segment from low single-digit to mid-single-digit, which directly contributes to the upward revision of the Life Science business guidance from flat to down 3% to flat to 1% for the full year. This is not merely an additive effect; the combination of the QX Continuum and QX700 Series products is strategically positioned to expand the ddPCR market by targeting lower-throughput customers through simplified workflows and flexible pricing, thereby capturing share from traditional qPCR users and unlocking new applications in clinical diagnostics where partners like Incyte Molecular Diagnostics and Genoscopy are advancing FDA-cleared assays for kidney transplant monitoring and colon cancer screening—both of which have achieved significant milestones such as NCCN guideline inclusion, creating a de facto reimbursement pathway that could drive durable, recurring reagent sales independent of volatile academic funding cycles. The market appears to be underestimating the structural shift toward ddPCR as a complementary or even preferred technology to NGS for specific use cases due to its speed, cost efficiency, and precision, a trend that could sustain growth even if academic instrument demand remains soft.
Despite persistent softness in the academic and biotech research markets, Bio-Rad is demonstrating resilience through durable consumable demand, particularly in its Droplet Digital PCR and food safety segments, which are less sensitive to capital expenditure cycles and more tied to recurring operational needs. The company noted that consumable demand from academic customers is proving more durable than prior expectations, a trend supported by high single-digit growth in ddPCR consumables year-over-year and stabilization in food safety sales, which continue to grow at high single-digit rates due to their application in regulated, non-discretionary markets like food safety and environmental testing. This durability is further reinforced by the shift in customer behavior toward maintaining research continuity despite funding uncertainty, as highlighted by management’s observation that academic customers are “focused on keeping their people and keeping the research going,” translating into sustained assay and reagent usage even when instrument purchases are deferred. This dynamic creates a predictable, annuity-like revenue stream that mitigates the cyclicality traditionally associated with life science equipment sales and provides a buffer against macroeconomic headwinds.
The company’s proactive management of tariff exposure has significantly reduced a previously feared headwind, with management revising the estimated tariff impact on operating margin from up to 130 basis points to just 30–40 basis points, a direct result of supply chain diversification, supplier collaboration, and increased manufacturing flexibility—including replicated capabilities and adaptive sourcing strategies—that were implemented without overinvestment amid uncertainty. This operational agility, combined with the easing of trade tensions with China and delayed tariff implementations elsewhere, has allowed Bio-Rad to upgrade its full-year 2025 non-GAAP gross margin guidance to 53.5%–54.5% (from 53%–54.5%) and operating margin to 12%–13% (from 10%–12%), reflecting not just cost control but improved absorption from manufacturing efficiencies and favorable product mix shifts driven by consumable pull-through. The market may be overlooking how these structural supply chain improvements—born from necessity but now embedded in operations—could become a lasting competitive advantage, enabling the company to maintain margin resilience even if geopolitical tensions resurge, and positioning it to outperform peers less prepared for such volatility.

▼ Bear case

Bio-Rad’s continued reliance on the volatile academic and biotech research markets poses a structural risk that is being underestimated, as evidenced by the persistent softness in core Life Science Group revenue excluding process chromatography, which declined 1.7% on a reported basis and 2.7% on a currency-neutral basis in Q2 2025, reflecting ongoing weakness in instrument demand driven by constrained government funding and delayed capital expenditures. Despite management’s optimism about durable consumable demand, the underlying trend shows that academic customers are deferring instrument purchases—a leading indicator of future consumable demand—while the company’s food safety segment, though growing at high single-digit rates, remains a small fraction of total revenue and cannot offset broad-based weakness in its core life science franchises. The stabilization in academic consumables noted by management may be temporary and tied to short-term budget flushes or grant cycles rather than a sustainable shift, especially given the global nature of academic funding pressures, with Europe shifting budgets to defense and Asia-Pacific (particularly China) remaining soft, suggesting that any near-term resilience in consumables could reverse as multi-year grant funding dries up without replacement.
The company’s heavy dependence on its equity stake in Sartorius AG as a driver of reported earnings creates a significant distraction and potential source of volatility, with the change in fair market value of this holding contributing $250 million to reported net income in Q2 2025—more than triple the $71 million in non-GAAP net income—thereby distorting the true operational performance and masking underlying business weakness. While management appropriately excludes this impact in non-GAAP measures, the market’s focus on headline GAAP earnings (which reached $318 million or $11.67 per diluted share) may lead to an inflated perception of profitability, especially as the Sartorius stake’s value is subject to external market forces beyond Bio-Rad’s control, including broader biotech sector sentiment and European regulatory or macroeconomic shifts. This reliance on investment gains rather than operational growth raises concerns about the quality of earnings and suggests that the company’s core business may not be generating sufficient internal cash flow to support its ambitious share repurchase program, which saw $139 million deployed in Q2 2025 alone at an average price of ~$234 per share, potentially sacrificing strategic investments in R&D or sales force expansion for short-term shareholder returns.
Bio-Rad’s guidance revisions reveal a troubling trend of diminishing growth ambitions, with the full-year 2025 currency-neutral revenue outlook now tightened to flat to 1% (from a prior range of flat to down 3% for Life Science and 0.5% to 2.5% for Diagnostics), reflecting a consensus view of prolonged stagnation rather than recovery, and the decision to postpone its Investor Day from fall 2025 to spring 2026 signals a lack of confidence in near-term narrative control amid persistent market volatility and geopolitical uncertainty. The company’s acknowledgment that it has not factored in any potential “end of year budget flush” upside—despite noting it as a possible source of unmodeled optimism—further underscores its cautious, almost defensive posture, suggesting that management does not believe a meaningful recovery in academic or biotech spending is imminent. This conservatism, combined with the reliance on tactical maneuvers like tariff mitigation and consumable mix shifts to drive margin expansion, indicates that Bio-Rad is increasingly focused on defending its current position rather than pursuing transformative growth, leaving it vulnerable to disruption from more agile competitors or technological shifts in adjacent markets like next-generation sequencing or digital health diagnostics that could erode its differentiated assay franchises over time.

Bio-Rad’s continued reliance on the volatile academic and biotech research markets poses a structural risk that is being underestimated, as evidenced by the persistent softness in core Life Science Group revenue excluding process chromatography, which declined 1.7% on a reported basis and 2.7% on a currency-neutral basis in Q2 2025, reflecting ongoing weakness in instrument demand driven by constrained government funding and delayed capital expenditures. Despite management’s optimism about durable consumable demand, the underlying trend shows that academic customers are deferring instrument purchases—a leading indicator of future consumable demand—while the company’s food safety segment, though growing at high single-digit rates, remains a small fraction of total revenue and cannot offset broad-based weakness in its core life science franchises. The stabilization in academic consumables noted by management may be temporary and tied to short-term budget flushes or grant cycles rather than a sustainable shift, especially given the global nature of academic funding pressures, with Europe shifting budgets to defense and Asia-Pacific (particularly China) remaining soft, suggesting that any near-term resilience in consumables could reverse as multi-year grant funding dries up without replacement.
The company’s heavy dependence on its equity stake in Sartorius AG as a driver of reported earnings creates a significant distraction and potential source of volatility, with the change in fair market value of this holding contributing $250 million to reported net income in Q2 2025—more than triple the $71 million in non-GAAP net income—thereby distorting the true operational performance and masking underlying business weakness. While management appropriately excludes this impact in non-GAAP measures, the market’s focus on headline GAAP earnings (which reached $318 million or $11.67 per diluted share) may lead to an inflated perception of profitability, especially as the Sartorius stake’s value is subject to external market forces beyond Bio-Rad’s control, including broader biotech sector sentiment and European regulatory or macroeconomic shifts. This reliance on investment gains rather than operational growth raises concerns about the quality of earnings and suggests that the company’s core business may not be generating sufficient internal cash flow to support its ambitious share repurchase program, which saw $139 million deployed in Q2 2025 alone at an average price of ~$234 per share, potentially sacrificing strategic investments in R&D or sales force expansion for short-term shareholder returns.
Bio-Rad’s guidance revisions reveal a troubling trend of diminishing growth ambitions, with the full-year 2025 currency-neutral revenue outlook now tightened to flat to 1% (from a prior range of flat to down 3% for Life Science and 0.5% to 2.5% for Diagnostics), reflecting a consensus view of prolonged stagnation rather than recovery, and the decision to postpone its Investor Day from fall 2025 to spring 2026 signals a lack of confidence in near-term narrative control amid persistent market volatility and geopolitical uncertainty. The company’s acknowledgment that it has not factored in any potential “end of year budget flush” upside—despite noting it as a possible source of unmodeled optimism—further underscores its cautious, almost defensive posture, suggesting that management does not believe a meaningful recovery in academic or biotech spending is imminent. This conservatism, combined with the reliance on tactical maneuvers like tariff mitigation and consumable mix shifts to drive margin expansion, indicates that Bio-Rad is increasingly focused on defending its current position rather than pursuing transformative growth, leaving it vulnerable to disruption from more agile competitors or technological shifts in adjacent markets like next-generation sequencing or digital health diagnostics that could erode its differentiated assay franchises over time.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password